Nina Kreuzberger1, Caroline Hirsch1, Marike Andreas1, Lena Böhm2, Paul J Bröckelmann3,4, Veronica Di Cristanziano5, Martin Golinski6, Renate Ilona Hausinger7, Sibylle Mellinghoff3,8, Berit Lange9,10, Tina Lischetzki1, Verena Kappler7, Agata Mikolajewska11,12, Ina Monsef1, Yun Soo Park1, Vanessa Piechotta1, Christoph Schmaderer7, Miriam Stegemann11, Kanika Vanshylla5, Florencia Weber2, Stephanie Weibel2, Caspar Stephani6, Nicole Skoetz1. 1. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. 2. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Wuerzburg, Germany. 3. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. 4. Max-Planck Institute for the Biology of Ageing, Cologne, Germany. 5. Laboratory of Experimental Immunology, Institute of Virology, University Hospital of Cologne, Cologne, Germany. 6. Department of Anesthesiology, University of Goettingen Medical Center, Goettingen, Germany. 7. Department of Nephrology, Klinikum rechts der Isar, TUM School of Medicine, Technical University of Munich, Munich, Germany. 8. German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Germany. 9. Department of Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany. 10. Translational Unit BBD, German Center for Infection Research (DZIF), Brunswick, Germany. 11. Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. 12. Centre for Biological Threats and Special Pathogens (ZBS), Strategy and Incident Response (ZBS7), Clinical Management and Infection Control (ZBS7.1), Robert Koch Institute, Berlin, Germany.
Abstract
BACKGROUND: High efficacy in terms of protection from severe COVID-19 has been demonstrated for several SARS-CoV-2 vaccines. However, patients with compromised immune status develop a weaker and less stable immune response to vaccination. Strong immune response may not always translate into clinical benefit, therefore it is important to synthesise evidence on modified schemes and types of vaccination in these population subgroups for guiding health decisions. As the literature on COVID-19 vaccines continues to expand, we aimed to scope the literature on multiple subgroups to subsequently decide on the most relevant research questions to be answered by systematic reviews. OBJECTIVES: To provide an overview of the availability of existing literature on immune response and long-term clinical outcomes after COVID-19 vaccination, and to map this evidence according to the examined populations, specific vaccines, immunity parameters, and their way of determining relevant long-term outcomes and the availability of mapping between immune reactivity and relevant outcomes. SEARCH METHODS: We searched the Cochrane COVID-19 Study Register, the Web of Science Core Collection, and the World Health Organization COVID-19 Global literature on coronavirus disease on 6 December 2021. SELECTION CRITERIA: We included studies that published results on immunity outcomes after vaccination with BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, Sputnik V or Sputnik Light, BBIBP-CorV, or CoronaVac on predefined vulnerable subgroups such as people with malignancies, transplant recipients, people undergoing renal replacement therapy, and people with immune disorders, as well as pregnant and breastfeeding women, and children. We included studies if they had at least 100 participants (not considering healthy control groups); we excluded case studies and case series. DATA COLLECTION AND ANALYSIS: We extracted data independently and in duplicate onto an online data extraction form. Data were represented as tables and as online maps to show the frequency of studies for each item. We mapped the data according to study design, country of participant origin, patient comorbidity subgroup, intervention, outcome domains (clinical, safety, immunogenicity), and outcomes. MAIN RESULTS: Out of 25,452 identified records, 318 studies with a total of more than 5 million participants met our eligibility criteria and were included in the review. Participants were recruited mainly from high-income countries between January 2020 and 31 October 2021 (282/318); the majority of studies included adult participants (297/318). Haematological malignancies were the most commonly examined comorbidity group (N = 54), followed by solid tumours (N = 47), dialysis (N = 48), kidney transplant (N = 43), and rheumatic diseases (N = 28, 17, and 15 for mixed diseases, multiple sclerosis, and inflammatory bowel disease, respectively). Thirty-one studies included pregnant or breastfeeding women. The most commonly administered vaccine was BNT162b2 (N = 283), followed by mRNA-1273 (N = 153), AZD1222 (N = 66), Ad26.COV2.S (N = 42), BBIBP-CorV (N = 15), CoronaVac (N = 14), and Sputnik V (N = 5; no studies were identified for Sputnik Light). Most studies reported outcomes after regular vaccination scheme. The majority of studies focused on immunogenicity outcomes, especially seroconversion based on binding antibody measurements and immunoglobulin G (IgG) titres (N = 179 and 175, respectively). Adverse events and serious adverse events were reported in 126 and 54 studies, whilst SARS-CoV-2 infection irrespective of severity was reported in 80 studies. Mortality due to SARS-CoV-2 infection was reported in 36 studies. Please refer to our evidence gap maps for more detailed information. AUTHORS' CONCLUSIONS: Up to 6 December 2021, the majority of studies examined data on mRNA vaccines administered as standard vaccination schemes (two doses approximately four to eight weeks apart) that report on immunogenicity parameters or adverse events. Clinical outcomes were less commonly reported, and if so, were often reported as a secondary outcome observed in seroconversion or immunoglobulin titre studies. As informed by this scoping review, two effectiveness reviews (on haematological malignancies and kidney transplant recipients) are currently being conducted.
BACKGROUND: High efficacy in terms of protection from severe COVID-19 has been demonstrated for several SARS-CoV-2 vaccines. However, patients with compromised immune status develop a weaker and less stable immune response to vaccination. Strong immune response may not always translate into clinical benefit, therefore it is important to synthesise evidence on modified schemes and types of vaccination in these population subgroups for guiding health decisions. As the literature on COVID-19 vaccines continues to expand, we aimed to scope the literature on multiple subgroups to subsequently decide on the most relevant research questions to be answered by systematic reviews. OBJECTIVES: To provide an overview of the availability of existing literature on immune response and long-term clinical outcomes after COVID-19 vaccination, and to map this evidence according to the examined populations, specific vaccines, immunity parameters, and their way of determining relevant long-term outcomes and the availability of mapping between immune reactivity and relevant outcomes. SEARCH METHODS: We searched the Cochrane COVID-19 Study Register, the Web of Science Core Collection, and the World Health Organization COVID-19 Global literature on coronavirus disease on 6 December 2021. SELECTION CRITERIA: We included studies that published results on immunity outcomes after vaccination with BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, Sputnik V or Sputnik Light, BBIBP-CorV, or CoronaVac on predefined vulnerable subgroups such as people with malignancies, transplant recipients, people undergoing renal replacement therapy, and people with immune disorders, as well as pregnant and breastfeeding women, and children. We included studies if they had at least 100 participants (not considering healthy control groups); we excluded case studies and case series. DATA COLLECTION AND ANALYSIS: We extracted data independently and in duplicate onto an online data extraction form. Data were represented as tables and as online maps to show the frequency of studies for each item. We mapped the data according to study design, country of participant origin, patient comorbidity subgroup, intervention, outcome domains (clinical, safety, immunogenicity), and outcomes. MAIN RESULTS: Out of 25,452 identified records, 318 studies with a total of more than 5 million participants met our eligibility criteria and were included in the review. Participants were recruited mainly from high-income countries between January 2020 and 31 October 2021 (282/318); the majority of studies included adult participants (297/318). Haematological malignancies were the most commonly examined comorbidity group (N = 54), followed by solid tumours (N = 47), dialysis (N = 48), kidney transplant (N = 43), and rheumatic diseases (N = 28, 17, and 15 for mixed diseases, multiple sclerosis, and inflammatory bowel disease, respectively). Thirty-one studies included pregnant or breastfeeding women. The most commonly administered vaccine was BNT162b2 (N = 283), followed by mRNA-1273 (N = 153), AZD1222 (N = 66), Ad26.COV2.S (N = 42), BBIBP-CorV (N = 15), CoronaVac (N = 14), and Sputnik V (N = 5; no studies were identified for Sputnik Light). Most studies reported outcomes after regular vaccination scheme. The majority of studies focused on immunogenicity outcomes, especially seroconversion based on binding antibody measurements and immunoglobulin G (IgG) titres (N = 179 and 175, respectively). Adverse events and serious adverse events were reported in 126 and 54 studies, whilst SARS-CoV-2 infection irrespective of severity was reported in 80 studies. Mortality due to SARS-CoV-2 infection was reported in 36 studies. Please refer to our evidence gap maps for more detailed information. AUTHORS' CONCLUSIONS: Up to 6 December 2021, the majority of studies examined data on mRNA vaccines administered as standard vaccination schemes (two doses approximately four to eight weeks apart) that report on immunogenicity parameters or adverse events. Clinical outcomes were less commonly reported, and if so, were often reported as a secondary outcome observed in seroconversion or immunoglobulin titre studies. As informed by this scoping review, two effectiveness reviews (on haematological malignancies and kidney transplant recipients) are currently being conducted.
Authors: Thomas Perkmann; Nicole Perkmann-Nagele; Thomas Koller; Patrick Mucher; Astrid Radakovics; Rodrig Marculescu; Michael Wolzt; Oswald F Wagner; Christoph J Binder; Helmuth Haslacher Journal: Microbiol Spectr Date: 2021-06-30
Authors: David Hillus; Tatjana Schwarz; Pinkus Tober-Lau; Kanika Vanshylla; Hana Hastor; Charlotte Thibeault; Stefanie Jentzsch; Elisa T Helbig; Lena J Lippert; Patricia Tscheak; Marie Luisa Schmidt; Johanna Riege; André Solarek; Christof von Kalle; Chantip Dang-Heine; Henning Gruell; Piotr Kopankiewicz; Norbert Suttorp; Christian Drosten; Harald Bias; Joachim Seybold; Florian Klein; Florian Kurth; Victor Max Corman; Leif Erik Sander Journal: Lancet Respir Med Date: 2021-08-13 Impact factor: 30.700
Authors: Fabian Schmidt; Frauke Muecksch; Yiska Weisblum; Justin Da Silva; Eva Bednarski; Alice Cho; Zijun Wang; Christian Gaebler; Marina Caskey; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz Journal: N Engl J Med Date: 2021-12-30 Impact factor: 91.245
Authors: Sandile Cele; Laurelle Jackson; David S Khoury; Khadija Khan; Thandeka Moyo-Gwete; Houriiyah Tegally; James Emmanuel San; Deborah Cromer; Cathrine Scheepers; Daniel G Amoako; Farina Karim; Mallory Bernstein; Gila Lustig; Derseree Archary; Muneerah Smith; Yashica Ganga; Zesuliwe Jule; Kajal Reedoy; Shi-Hsia Hwa; Jennifer Giandhari; Jonathan M Blackburn; Bernadett I Gosnell; Salim S Abdool Karim; Willem Hanekom; Anne von Gottberg; Jinal N Bhiman; Richard J Lessells; Mahomed-Yunus S Moosa; Miles P Davenport; Tulio de Oliveira; Penny L Moore; Alex Sigal Journal: Nature Date: 2021-12-23 Impact factor: 49.962
Authors: Ainsley Ryan Yan Bin Lee; Shi Yin Wong; Louis Yi Ann Chai; Soo Chin Lee; Matilda Xinwei Lee; Mark Dhinesh Muthiah; Sen Hee Tay; Chong Boon Teo; Benjamin Kye Jyn Tan; Yiong Huak Chan; Raghav Sundar; Yu Yang Soon Journal: BMJ Date: 2022-03-02
Authors: Wanwisa Dejnirattisai; Robert H Shaw; Piyada Supasa; Chang Liu; Arabella Sv Stuart; Andrew J Pollard; Xinxue Liu; Teresa Lambe; Derrick Crook; Dave I Stuart; Juthathip Mongkolsapaya; Jonathan S Nguyen-Van-Tam; Matthew D Snape; Gavin R Screaton Journal: Lancet Date: 2021-12-20 Impact factor: 79.321
Authors: Verena Klemis; David Schub; Tina Schmidt; Janine Mihm; Franziska Hielscher; Stefanie Marx; Amina Abu-Omar; Laura Ziegler; Candida Guckelmus; Rebecca Urschel; Sophie Schneitler; Sören L Becker; Barbara C Gärtner; Urban Sester; Martina Sester Journal: Nat Med Date: 2021-07-26 Impact factor: 53.440